Wells Fargo’s GALENA BIOPHARMA INC COM RXII Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | – | Sell |
-177,335
| Closed | -$62K | – | 6708 |
|
|
2016
Q3 | $62K | Sell |
177,335
-15,000
| -8% | -$5.24K | ﹤0.01% | 5194 |
|
|
2016
Q2 | $90K | Sell |
192,335
-50,612
| -21% | -$23.7K | ﹤0.01% | 4896 |
|
|
2016
Q1 | $330K | Buy |
242,947
+13,393
| +6% | +$18.2K | ﹤0.01% | 4117 |
|
|
2015
Q4 | $338K | Buy |
229,554
+81,703
| +55% | +$120K | ﹤0.01% | 4140 |
|
|
2015
Q3 | $233K | Sell |
147,851
-80,155
| -35% | -$126K | ﹤0.01% | 4379 |
|
|
2015
Q2 | $388K | Buy |
228,006
+67,555
| +42% | +$115K | ﹤0.01% | 4243 |
|
|
2015
Q1 | $223K | Buy |
160,451
+18,116
| +13% | +$25.2K | ﹤0.01% | 4368 |
|
|
2014
Q4 | $214K | Sell |
142,335
-3,103
| -2% | -$4.67K | ﹤0.01% | 4382 |
|
|
2014
Q3 | $300K | Buy |
145,438
+49,837
| +52% | +$103K | ﹤0.01% | 4166 |
|
|
2014
Q2 | $293K | Buy |
95,601
+27,430
| +40% | +$84.1K | ﹤0.01% | 4190 |
|
|
2014
Q1 | $170K | Buy |
68,171
+39,418
| +137% | +$98.3K | ﹤0.01% | 4412 |
|
|
2013
Q4 | $143K | Buy |
28,753
+25,588
| +808% | +$127K | ﹤0.01% | 4394 |
|
|
2013
Q3 | $7K | Sell |
3,165
-2,000
| -39% | -$4.42K | ﹤0.01% | 5225 |
|
|
2013
Q2 | $11K | Buy |
+5,165
| New | +$11K | ﹤0.01% | 5054 |
|
Wells Fargo's RXII Position: Q4 2016 in Review
Wells Fargo sold out of GALENA BIOPHARMA INC COM (RXII) in Q4 2016, closing a stake of 177,335 shares — an estimated $62K sold.
Wells Fargo first reported a position in RXII in Q2 2013 and held it in 14 quarters. The position peaked at $388K in Q2 2015. 0 funds tracked by Wall St. Rank hold RXII as of Q4 2016.
- Wells Fargo reported no remaining GALENA BIOPHARMA INC COM position as of Q4 2016 after selling out during the quarter.
- Wells Fargo sold 177,335 GALENA BIOPHARMA INC COM shares in Q4 2016, an estimated $62K.
- Wells Fargo first reported a position in GALENA BIOPHARMA INC COM in Q2 2013 and held it in 14 quarters.
- Wells Fargo's GALENA BIOPHARMA INC COM position peaked at $388K in Q2 2015.
- 0 funds tracked by Wall St. Rank held GALENA BIOPHARMA INC COM as of Q4 2016.
Based on Wells Fargo's 13F filing for Q4 2016, filed 1 Feb 2017.